PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-7.00%
Negative revenue growth while AVGO stands at 6.05%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-6.56%
Negative gross profit growth while AVGO is at 12.78%. Joel Greenblatt would examine cost competitiveness or demand decline.
-0.77%
Negative EBIT growth while AVGO is at 71.91%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-1.89%
Negative operating income growth while AVGO is at 71.91%. Joel Greenblatt would press for urgent turnaround measures.
4.76%
Net income growth under 50% of AVGO's 78.75%. Michael Burry would suspect the firm is falling well behind a key competitor.
3.90%
EPS growth under 50% of AVGO's 75.82%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
5.26%
Diluted EPS growth under 50% of AVGO's 78.57%. Michael Burry would worry about an eroding competitive position or excessive dilution.
-0.82%
Share reduction while AVGO is at 4.15%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.77%
Reduced diluted shares while AVGO is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
11.84%
Dividend growth above 1.5x AVGO's 7.09%. David Dodd would verify if the firm's cash flow is robust enough for these payouts.
1.49%
Positive OCF growth while AVGO is negative. John Neff would see this as a clear operational advantage vs. the competitor.
-0.31%
Negative FCF growth while AVGO is at 7.21%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
40.82%
10Y revenue/share CAGR under 50% of AVGO's 219.16%. Michael Burry would suspect a lasting competitive disadvantage.
4.85%
5Y revenue/share CAGR under 50% of AVGO's 182.05%. Michael Burry would suspect a significant competitive gap or product weakness.
17.82%
3Y revenue/share CAGR under 50% of AVGO's 165.37%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
149.80%
10Y OCF/share CAGR at 50-75% of AVGO's 295.84%. Martin Whitman might fear a structural deficiency in operational efficiency.
34.74%
Below 50% of AVGO's 135.16%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
45.06%
3Y OCF/share CAGR under 50% of AVGO's 141.27%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
102.44%
Below 50% of AVGO's 1747.95%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
2.85%
Below 50% of AVGO's 129.36%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
248.52%
3Y net income/share CAGR above 1.5x AVGO's 140.48%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
32.16%
Below 50% of AVGO's 368.60%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
10.44%
Below 50% of AVGO's 174.64%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-0.13%
Negative 3Y equity/share growth while AVGO is at 73.69%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
1175.51%
Dividend/share CAGR of 1175.51% while AVGO is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
192.39%
Dividend/share CAGR of 192.39% while AVGO is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
80.78%
Below 50% of AVGO's 165.11%. Michael Burry suspects the firm invests elsewhere or can’t match the competitor’s dividend policy.
-21.34%
Firm’s AR is declining while AVGO shows 25.96%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-4.52%
Inventory is declining while AVGO stands at 3.35%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-1.87%
Negative asset growth while AVGO invests at 6.05%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
0.58%
Under 50% of AVGO's 5.73%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-0.29%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-3.16%
Our R&D shrinks while AVGO invests at 3.99%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-6.68%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.